Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
November 05 2024 - 4:43PM
Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq:
TVGN), a clinical-stage specialty immunotherapy biotech developing
off-the-shelf, genetically unmodified T cell therapeutics to treat
infectious disease and cancers, is pleased to announce that its
Founder and CEO, Dr. Ryan Saadi, MD, MPH, has been recognized by
ROI-NJ as an Influencer in the Health Care sector. This
acknowledgment highlights Tevogen Bio’s commitment to delivering
advanced immunotherapies at a commercially viable and economically
sustainable price.
“In today’s market reality, efficiency and affordability are
essential for sustainable business success. One important decision
for biotech founders is how much equity to retain, a choice that
reflects their commitment to the company’s mission and appeals to
investors and partners with a shared purpose. Guided by these
principles, Tevogen Bio is a fully operational biotech with assets
valued in excess of $10 billion by our investors, all achieved with
under $40 million in expenditures.” commented Ryan Saadi, MD, MPH,
Founder and CEO of Tevogen Bio. “Tevogen Bio’s ~78% ownership of
common stock by company officers is a testament to our discipline,
cost-efficient model, and commitment to meaningful progress.”
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company
harnessing CD8+ cytotoxic T lymphocytes, to develop off-the-shelf,
genetically unmodified T cell therapeutics to treat infectious
disease and cancers, aiming to address the significant unmet needs
of large patient populations. Tevogen leadership believes that
sustainability and commercial success in the current era of
healthcare rely on ensuring patient accessibility through advanced
science and innovative business models. Tevogen has reported
positive safety data from its proof-of-concept clinical trial, and
its key intellectual property assets are wholly owned by the
company, not subject to any third-party licensing agreements. These
assets include three granted patents and numerous pending patents,
two of which are related to artificial intelligence.
Tevogen is driven by a team of experienced industry leaders and
scientists with drug development and global product launch
experience. Tevogen’s leadership believes that accessible
personalized therapeutics are the next frontier of medicine, and
that disruptive business models are required to sustain medical
innovation.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/7de0f8f6-72e5-430d-a5e8-d283d26ec6d2
Tevogen Bio (NASDAQ:TVGN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Tevogen Bio (NASDAQ:TVGN)
Historical Stock Chart
From Dec 2023 to Dec 2024